Tyler Kuhk
Nurse Practitioner · Bellevue, WANPI 1467810283
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Sanofi at 47.5% of the total. 2025 is the largest year on record at $18,651, 7.3 times the $2,570 reported in 2021. Among nurse practitioner clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $270.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$16K
- AstraZeneca$9K
- Regeneron Healthcare Solutions, Inc.$5K
- Mylan Specialty L.p.$1K
- GSK$416
- Bayer$400
- plus $893 from 5 others
What the payments were for
- Consulting fees$13,39641%
- Speaking & faculty fees$10,92833%
- Travel & lodging$4,77315%
- Food & beverage$3,61111%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 20 | $15,562 |
| AstraZeneca | 24 | $8,988 |
| Regeneron Healthcare Solutions, Inc. | 34 | $5,483 |
| Mylan Specialty L.p. | 5 | $1,041 |
| GSK | 23 | $416 |
| Bayer | 2 | $400 |
| United Therapeutics Corporation | 6 | $362 |
| Pulmonx Corporation | 2 | $197 |
| Verona Pharma, Inc. | 3 | $195 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Viatris Specialty LLC | 1 | $63 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$23,640
- BREZTRI$2,428
- FASENRA$1,105
- Yupelri$1,032
- Adempas$400
- ZEPHYR ENDOBRONCHIAL VALVE$150
- Ohtuvayre$121
- TRELEGY ELLIPTA$121
- NUCALA$120
How this compares
$32,783 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 174 | $129,232 |
| Breo ElliptaFluticasone/Vilanterol | 125 | $64,868 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $37,047 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $26,982 |
| Spiriva RespimatTiotropium Bromide | 15 | $14,135 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $11,885 |
| Arnuity ElliptaFluticasone Furoate | 15 | $6,416 |
| DuleraMometasone/Formoterol | 16 | $6,186 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $4,740 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $3,880 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 113 | $2,895 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,669 |
| Montelukast Sodium | 151 | $1,636 |
| Ventolin HfaAlbuterol Sulfate | 16 | $1,288 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 18 | $1,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $416 | $200,516314 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $8,988 | $48,93269 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Other nurse practitioner in Bellevue
- Amaris MurphyBellevue$146K
- Kate KennedyBellevue$63K
- Wenting JiangBellevue$5K
- Olga VoloshinaSeattle$279K
- Sandra ChristensenSeattle$244K
- Felicia ForrestLynnwood$206K
- Sonia GlennieSeattle$78K
- Megan WildesTacoma$72K
- Vicki HainesPasco$57K
- Jessica ArmitageSumner$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.